Press releases of industry-sponsored clinical trials in oncology: Characteristics, timing and financial impact
Most PRs announce firstly the positivity of a clinical trial, without detailed results. The market appears to absorb this information with minimal stock price adjustments.
Authors
- Cecilia Conte
- Massimo Di Maïo (ORCID: https://orcid.org/0000-0001-8906-3785)
- Oriana Ciani (ORCID: https://orcid.org/0000-0002-3607-0508)
- Maria Lucia Iacovino (ORCID: https://orcid.org/0000-0001-9957-6170)
- Anna Amela Valsecchi (ORCID: https://orcid.org/0009-0007-4940-5761)
- Eleonora Paganoni
- Francesco Perrone (ORCID: https://orcid.org/0000-0002-9738-0526)
- Letizia Galeasso
- Nicola Maria Fiore
- Daniele Ierace
Institutions
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Fondazione Ricerca Molinette (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Turin (IT)
- Bocconi University (IT)
Publication Details
- Journal
- Journal of Cancer Policy
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1016/j.jcpo.2025.100587
- Citations
- 2
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 2.33